Breaking News

TransAsia Air Flight Crashed in Taiwan, Official Confirms
Tweet TWEET

Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming GRS and IGF Society Congress

  Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at
                    Upcoming GRS and IGF Society Congress

PR Newswire

QUÉBEC CITY, Oct. 10, 2012

QUÉBEC CITY, Oct. 10, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX:AEZ) (the"Company") today announced that George R. Merriam, MD,
Director of the Clinical Study Unit at the VA Puget Sound Health Care System,
and Professor of Medicine at the University of Washington, Seattle and Tacoma,
WA, will give an oral presentation on AEZS-130, Aeterna Zentaris' ghrelin
agonist, at the 6^th International Congress of the Growth Hormone Research
(GRS) and Insulin-like Growth Factor (IGF) Society, which will be held in
Munich, Germany, October 17-20, 2012.

The presentation titled, "Use of an orally-active ghrelin mimetic, macimorelin
(AEZS-130), as a safe, simple test for Adult Growth Hormone Deficiency (AGHD):
Effect of BMI on optimal cut off ", will take place on Thursday, October 18,
2012, from 4:30 to 4:45 pm (local time), in the Black Box Room of the Gasteig
Conference Center.

About AEZS-130

AEZS-130, a ghrelin agonist, is a novel orally-active small molecule that
stimulates the secretion of growth hormone. The Company has completed a Phase
3 trial for use as an oral diagnostic test for AGHD. AEZS-130 has been granted
orphan drug designation by the FDA for use in this indication. Aeterna
Zentaris owns the worldwide rights to AEZS-130.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company
currently investigating treatments for various unmet medical needs. The
Company's pipeline encompasses compounds at all stages of development, from
drug discovery through to marketed products. For more information please visit
www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.

Contact:

Investor Relations
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265
gvallieres@aezsinc.com

Media Relations
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
pburroughs@aezsinc.com